Status: Recruiting
Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists
The main purpose of the study is to collect information about how the device functions in a variety of treatment areas and skin types and to find out what changes, if any, occur in the skin treated with the study device compared to the skin that wasn't treated including patients receiving GLP-1's, a class of medications that mimic a natural hormone to help control blood sugar and support weight loss. The study will also evaluate side effects that occur with this treatment, if any. Standardized 2D Imaging will be used to quantify reduction of wrinkle severity
Participants needed: 10
Trial details
Age: 30-65Biological sex: AllType: ObservationalSponsor: Cytrellis Biosystems, Inc.Updated: Dec 31, 2025Locations: 1
Eligibility criteria
Male and female adult, between the ages of 30 and 65 [+4]
Pregnant women or nursing mothers [+10]